Sign in
CompletedPhase 4

Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia

Key facts

Who runs it
Beijing Tongren Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
120 people enrolled
Started
30 Jun 2023
Ended
30 Jan 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • soft peripheral defocus contact lenses
  • Atropine 0.04%
  • Atropine (0.01%)
  • Single Vision Spectacles
Record updated
12 February 2026

Who can take part

Age
4 years to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Mainland Chinese children aged 4-16 years at enrollment
  • Spherical equivalent refraction ≤-6.0D in both eyes under cycloplegia
  • Astigmatism ≤2.5D in both eyes
  • Anisometropia ≤2.5D
  • Best corrected visual acuity ≥0.1 logMAR in both eyes
  • Subject-reported non-significant ocular and systemic medical history
  • Ability and willingness to wear contact lenses (for intervention groups)
  • Written informed consent from parents/guardians and assent from child
  • Ability to attend all scheduled follow-up visits

Who cannot take part

  • Previous use of myopia control treatments (atropine, orthokeratology, multifocal lenses) within 3 months
  • Current use of systemic medications affecting pupil size or accommodation
  • Current use of systemic medications that may significantly affect contact lens wear, tear film production, pupil size, adaptability, or refractive status
  • Known allergies to atropine or contact lens materials
  • Ocular diseases: strabismus, amblyopia, glaucoma, cataract, corneal disease
  • Systemic diseases affecting ocular health
  • History of ocular surgery or trauma
  • Inability to perform study procedures
  • Participation in other clinical trials within 2 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Peripheral contact lens in controlling myopia progression in high myopia children(PAM)is a prospective, single-center, randomized controlled trial with three parallel arms conducted at Beijing Tongren Hospital. Chinese children aged 6-12 years with high myopia (spherical equivalent ≤-6.0D) and annual progression ≥0.75D will be enrolled. Participants will be randomized 40:40:40 to: (1) combination therapy group receiving atropine 0.04% plus soft peripheral defocus contact lenses; (2) atropine monotherapy group receiving atropine 0.04% plus spectacles; or (3) control group receiving atropine 0.01% plus spectacles. The primary outcome is change in axial length and cycloplegic refraction at 24 months. Secondary outcomes include changes in pupil diameter, and safety parameters.

The 3 groups in the trial

  • combination therapy groupTreatment being tested

    40 patients in combination therapy group received atropine 0.04% plus soft peripheral defocus contact lenses

    Treatment: soft peripheral defocus contact lenses and Atropine 0.04%

  • atropine monotherapy groupTreatment being tested

    40 patients in atropine monotherapy group received atropine 0.04% plus spectacles

    Treatment: Atropine 0.04% and Single Vision Spectacles

  • control groupPlacebo, for comparison

    40 patients in control group received atropine 0.01% plus spectacles

    Treatment: Atropine (0.01%) and Single Vision Spectacles

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Study of Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia
Record updated
12 February 2026